{"createdAt":"8/2/2020, 2:34:37 PM","timestamp":1596393277273,"Company ID number":"624","DMX_ISSUER_NAME":"Guizhou Bailing Group Pharmaceutical Co Ltd","DMX_ISSUER_ID":"IID000000002591988","Country of Classification":"CHINA","name":"Guizhou Bailing Group Pharmaceutical Co Ltd ","code":"002424","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"贵州百灵企业集团制药股份有限公司_姜伟","group":"board","name":"姜伟","title":"董事长,董事","isMale":true,"age":"59","degree":"本科","salary":"0.00","stockAmount":"6.695亿","description":"姜伟先生:中国国籍,无境外居留权,男,1982年毕业于贵阳中医学院药学系,大学文化,高级工程师。历任安顺制药厂厂长、贵州百灵制药有限公司董事长、贵州百灵企业集团制药有限公司董事长、贵州百灵企业集团制药股份有限公司董事长。姜伟先生1997年当选安顺地区青年联合会第一届委员,安顺地区商会理事,贵州商会第八届执委,1998年当选安顺市第三届人大代表,1998年当选安顺地区政协委员,2000年当选安顺市政协委员,2002年当选第九届贵州省人大代表,2004年受聘为安顺市首批“市管专家”,2005年荣获“贵州省劳动模范”称号,2005年被评为贵州省优秀中国特色社会主义事业建设者,2006年当选为“贵州年度都市人物”,2007年当选第十届贵州省人大代表。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_牛民","group":"board","name":"牛民","title":"董事","isMale":true,"age":"50","degree":"中专","salary":"72.00万","stockAmount":"27.06万","description":"牛民先生:中国国籍,无境外居留权,男,50岁,中专学历,高级会计师。历任贵州百灵企业集团制药有限公司财务部长、副总经理,现任贵州百灵企业集团制药股份有限公司总经理、董事会秘书。2009年7月获得深圳证券交易所颁发的《董事会秘书资格证书》,证书编号为09012055。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_姜勇","group":"board","name":"姜勇","title":"董事","isMale":true,"age":"52","degree":"大专","salary":"72.00万","stockAmount":"1.56亿","description":"姜勇先生:中国国籍,无境外居留权,男,52岁,大专学历,高级经济师。历任安顺制药厂副厂长、贵州百灵制药有限公司副总经理、贵州百灵企业集团制药有限公司副总经理、贵州百灵企业集团制药股份有限公司副总经理。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_陈培","group":"board","name":"陈培","title":"董事","isMale":true,"age":"36","degree":"本科","salary":"72.00万","stockAmount":"22.83万","description":"陈培先生:中国国籍,无境外居留权,男,36岁,本科学历。2006年,北方工业大学经济管理系会计学本科毕业。2006年7月至2007年10月,在贵州诚智会计师事务所从事审计工作,2007年至2011年,在贵州百灵企业集团制药股份有限公司财务部从事财务工作;2011年至2013年,在贵州百灵企业集团制药股份有限公司供应部任供应部副部长,2013年至今任贵州百灵企业集团制药股份有限公司副总经理。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_况勋华","group":"board","name":"况勋华","title":"董事","isMale":true,"age":"49","degree":"大专","salary":"48.00万","stockAmount":"9.3万","description":"况勋华先生:中国国籍,无境外居留权,男,49岁,大专学历。1992年工作于重庆磷肥厂,1995年调重庆北恩集团有限公司,1998年底加入贵州百灵(原安顺制药厂)任四川办事处负责人,现任贵州百灵企业集团制药股份有限公司销售总监。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_钟国跃","group":"board","name":"钟国跃","title":"独立董事","isMale":true,"age":"62","degree":"博士","salary":"6.000万","stockAmount":"-","description":"钟国跃先生:中国国籍,无境外居留权,男,62岁,农工党员。1979年9月至1983年7月,本科就读于成都中医学院中药学专业;1992年8月至1996年1月,博士研究生就读于日本富山医科药科大学药学;1996年2月至1998年4月,博士后就读于中国药科大学。1983年7月至1998年11月,为四川省中药研究所研究员;1998年12至2012年1月,任重庆市中药研究院院长;2012年2月至今,任江西中医药大学主任、二级研究员。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_胡坚","group":"board","name":"胡坚","title":"独立董事","isMale":true,"age":"52","degree":"博士","salary":"--","stockAmount":"-","description":"胡坚先生:中国国籍,无境外居留权,男,52岁,博士研究生。1989年6月至1993年7月,本科就读于西南师范大学法学专业;1999年9月至2002年7月,硕士研究生就读于西南政法大学民商法(商法方向)专业;2002年9月至2011年1月,博士研究生就读于西南政法大学民商法(知识产权法方向)专业;2014年7月至2014年12月,在美国芝加哥大学做访问学者;1993年9月至今,任重庆大学经济与工商管理学院教授。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_王昱","group":"board","name":"王昱","title":"独立董事","isMale":true,"age":"38","degree":"博士","salary":"--","stockAmount":"-","description":"王昱先生:中国国籍,无境外居留权,男,38岁,博士研究生。2001年9月至2004年7月,本科就读于中国科学技术大学计算机科学与技术专业及管理学专业;2004年9月至2009年7月,博士研究生就读于中国科学技术大学管理科学与工程专业;2009年7月至今,在重庆大学经管学院任教。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_刘胜强","group":"board","name":"刘胜强","title":"独立董事","isMale":true,"age":"42","degree":"博士","salary":"--","stockAmount":"-","description":"刘胜强先生:中国国籍,无境外居留权,男,42岁,博士后。1999年6月至2000年7月,本科就读于武汉科技大学会计学专业;2001年9月至2004年7月,硕士研究生就读于武汉科技大学企业管理(财务管理方向)专业;2005年3月至2011年12月,博士研究生就读于重庆大学会计学专业;2012年8月至2016年7月,博士后就读于厦门大学会计学专业;2013年8月至2014年8月,在中国香港浸会大学做访问学者;2018年3月至2019年7月,在美国加州州立大学弗雷斯诺分校做访问学者;2004年至今,在重庆工商大学会计学院从事会计学的教学工作。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_夏文","group":"supervisoryCommittee","name":"夏文","title":"监事会主席","isMale":true,"age":"52","degree":"硕士","salary":"36.00万","stockAmount":"3.34万","description":"夏文先生:中国国籍,无境外居留权,男,52岁,硕士学位。1989年7月年毕业于贵阳中医学院医学系,本科学历,2012年12月,获得暨南大学高级管理人员工商管理硕士专业学位。1989年7月至2008年,在贵州天台山制药厂,曾任车间技术员、车间主任、副厂长;2000年8月至今,先后任贵州百灵企业集团制药有限公司学术部部长、贵州百灵企业集团制药股份有限公司学术部部长、贵州百灵企业集团制药股份有限公司研发总监。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_孙旭辰","group":"supervisoryCommittee","name":"孙旭辰","title":"监事","isMale":true,"age":"30","degree":"本科","salary":"0.00","stockAmount":"-","description":"孙旭辰先生:中国国籍,无境外居留权,男,30岁,本科学历。2011年7月毕业于贵州财经大学金融系金融专业;2011年1月-2012年5月,于华创证券有限责任公司贵阳北京路营业部工作;2012年6月-2017年3月,于华创证券有限责任公司运维中心工作;2017年3月-至今,于华创证券有限责任公司信用交易部工作,现任华创证券有限责任公司信用交易部高级副总监。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_龙东","group":"supervisoryCommittee","name":"龙东","title":"监事","isMale":true,"age":"44","degree":"本科","salary":"--","stockAmount":"-","description":"龙东先生:中国国籍,无境外居留权,男,44岁。2002年7月年毕业于贵阳中医学院中药学专业,本科学历。2002年7月至2003年3月,在贵州安顺地区制药厂大输液车间前后担任车间工人、灯检班长、QC、QA、技术员;2003年4月至2004年4月,在贵州安顺地区制药厂质量保证部担任质检员;2004年5月至2008年7月,在贵州百灵制药有限公司软胶囊车间担任副主任;2008年8月至今,在贵州百灵企业集团制药股份有限公司先后担任技术中心实验室主任兼前提取车间QA、片剂二车间主任、综合制剂四车间主任兼纯净水公司负责人、综合制剂四车间主任兼综合制剂一车间主任及纯净水公司总经理。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_李强","group":"supervisoryCommittee","name":"李强","title":"职工监事","isMale":true,"age":"42","degree":"本科","salary":"16.14万","stockAmount":"-","description":"李强先生:中国国籍,无境外居留权,男,42岁,本科学历。2001年毕业于贵阳中医学院中药制药专业,2011-2013年就读于贵州广播电视大学工商行政管理专业(在职)。2001年至今于贵州百灵企业集团制药有限公司、贵州百灵企业集团制药股份有限公司任职,先后从事人事部工作、车间管理工作,软胶囊车间主任,现任生产部副总监、颗粒车间主任。","lastUpdated":"2020-04-30"},{"id":"贵州百灵企业集团制药股份有限公司_蒋坤","group":"supervisoryCommittee","name":"蒋坤","title":"职工监事","isMale":true,"age":"36","degree":"本科","salary":"--","stockAmount":"-","description":"蒋坤先生:中国国籍,无境外居留权,男,36岁,本科学历。2007年7月年毕业于沈阳药科大学中药学专业,学士学位,执业药师,高级工程师,2017年,入选贵州省“千”层次创新型人才。2008年2月进入贵州百灵企业集团制药股份有限公司(以下简称贵州百灵)学术部工作;2013年6月起担任贵州百灵学术部研发主管;2015年2月,担任贵州百灵技术中心副主任;2018年6月,任贵州百灵前提取二车间副主任;2019年8月至今,任前提取二车间主任。","lastUpdated":"2020-04-30"},{"id":"贵州百灵企业集团制药股份有限公司_牛民","group":"manager","name":"牛民","title":"总经理,董事会秘书","isMale":true,"age":"50","degree":"中专","salary":"72.00万","stockAmount":"27.06万","description":"牛民先生:中国国籍,无境外居留权,男,50岁,中专学历,高级会计师。历任贵州百灵企业集团制药有限公司财务部长、副总经理,现任贵州百灵企业集团制药股份有限公司总经理、董事会秘书。2009年7月获得深圳证券交易所颁发的《董事会秘书资格证书》,证书编号为09012055。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_姜勇","group":"manager","name":"姜勇","title":"副总经理","isMale":true,"age":"52","degree":"大专","salary":"72.00万","stockAmount":"1.56亿","description":"姜勇先生:中国国籍,无境外居留权,男,52岁,大专学历,高级经济师。历任安顺制药厂副厂长、贵州百灵制药有限公司副总经理、贵州百灵企业集团制药有限公司副总经理、贵州百灵企业集团制药股份有限公司副总经理。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_陈培","group":"manager","name":"陈培","title":"副总经理","isMale":true,"age":"36","degree":"本科","salary":"72.00万","stockAmount":"22.83万","description":"陈培先生:中国国籍,无境外居留权,男,36岁,本科学历。2006年,北方工业大学经济管理系会计学本科毕业。2006年7月至2007年10月,在贵州诚智会计师事务所从事审计工作,2007年至2011年,在贵州百灵企业集团制药股份有限公司财务部从事财务工作;2011年至2013年,在贵州百灵企业集团制药股份有限公司供应部任供应部副部长,2013年至今任贵州百灵企业集团制药股份有限公司副总经理。","lastUpdated":"2020-05-21"},{"id":"贵州百灵企业集团制药股份有限公司_郑荣","group":"manager","name":"郑荣","title":"财务总监","isMale":false,"age":"49","degree":"本科","salary":"42.00万","stockAmount":"5.13万","description":"郑荣,女,1971年10月出生,本科学历,注册税务师、注册会计师、高级会计师。2001年至2003年,任贵州大仓隆仓储有限公司财务总监,2003年至2008年任贵州多彩贵州城建设经营有限公司财务部经理,2008年至2009年任贵州恒利会计师事务所副所长,2009年至2013年任贵州贵酒有限责任公司财务总监,2014年1月至今任贵州百灵企业集团制药股份有限公司财务总监。","lastUpdated":"2020-05-21"}],"companyName":"贵州百灵企业集团制药股份有限公司","province":"贵州省","englishName":"GZ Bailing Group Pharm. Co., Ltd.","industry":"医药生物 — 中药Ⅱ","website":"www.gzbl.com","mainBusiness":"从事止咳化痰用药、感冒用药、心脑血管用药等中成药的生产与销售","productsName":["银丹心脑通软胶囊","维C银翘片","咳速停糖浆","咳速停胶囊","小儿柴桂退热颗粒","金感胶囊","双羊喉痹通颗粒","泌淋清胶囊","康妇灵胶囊","复方一枝黄花喷雾剂","经带宁胶囊","消咳颗粒","肥料"],"actualController":"姜伟","actualControllerSharePercentage":"48.25%","registeredCapital":"14.11亿元","employeeAmount":"5961","phone":"86-0851-33415126","location":"贵州省安顺市西秀区经济技术开发区西航大道","chineseDescription":"贵州百灵企业集团制药股份有限公司是一家苗药研发、生产企业。公司的产品主要有咳化痰用药、感冒用药、心脑血管用药等中成药。公司按照拥有发明专利的苗药产品数量和2009年OTC类苗药产品销售额排名统计，位居全国第一，按照拥有药品批准文号的苗药产品数量和2009年单品种苗药销售额排名统计，公司位居全国第二。","foundedDate":"1999-03-25","goPublicDate":"2010-06-03","companyHistory":"贵州百灵企业集团制药股份有限公司（以下简称公司或本公司）系由贵州百灵企业集团制药有限公司整体变更设立,现持有统一社会信用代码为91520400215650676U的营业执照。贵州百灵企业集团制药有限公司于1999年3月25日在贵州安顺市工商行政管理局登记注册，总部位于贵州省安顺市，2007年12月26日，姜伟、姜勇、张锦芬以净资产折股（折合股本11,000万股）方式，发起设立贵州百灵企业集团制药股份有限公司。公司公开发行股票3,700万股，于2010年6月3日在深圳证券交易所挂牌交易。经过多次利润分配及资本公积转增股本后，公司现有注册资本1,411,200,000.00元，股份总数1,411,200,000股（每股面值1元），全部为流通股。其中：姜伟持有750,080,416股，占总股本的53.15%；姜勇持有155,971,200股，占总股本的11.05%；张锦芬持有104,151,301股，占总股本的7.38%。公司的实际控制人为自然人姜伟。收起▲","shareholders":[{"organizationId":"","holderName":"姜伟","totalShare":"6.88亿","sharePercentage":"48.75%"},{"organizationId":"","holderName":"姜勇","totalShare":"1.56亿","sharePercentage":"11.05%"},{"organizationId":"","holderName":"华创证券-证券行业支持民企发展系列之华创证券1号FOF单一资产管理计划-华创证券有限责任公司支持民企发展14号单一资产管理计划","totalShare":"8680.55万","sharePercentage":"6.15%"},{"organizationId":"","holderName":"华创证券-工商银行-华创证券有限责任公司支持民企发展1号集合资产管理计划","totalShare":"7454.10万","sharePercentage":"5.28%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"880.17万","sharePercentage":"0.62%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"840.43万","sharePercentage":"0.60%"},{"organizationId":"","holderName":"中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金","totalShare":"418.96万","sharePercentage":"0.30%"},{"organizationId":"","holderName":"张君鹏","totalShare":"326.67万","sharePercentage":"0.23%"},{"organizationId":"","holderName":"黄禹农","totalShare":"235.00万","sharePercentage":"0.17%"},{"organizationId":"","holderName":"包宇天","totalShare":"222.22万","sharePercentage":"0.16%"}],"englishDescription":"GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of Chinese patent medicines. The Company is also engaged in the provision of Chinese medicine materials. The Company is also engaged in the distribution of fertilizers and purified water, and the operation of medical institutions. The Company conducts its businesses mainly within domestic markets. ","englishIndustry":"Major Drugs","Price to earnings (ttm)":"60.27","Price to sales (ttm)":"4.51","Price to book (mrq)":"3.18","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"62.80","Lt debt to equity (mrq)":"6.29","Return on investment (ttm)":"5.08","Return on equity (ttm)":"3.16","Income statement":{"Revenue":"2,850.59","Total revenue":"2,850.59","Cost of revenue, total":"1,144.97","Gross profit":"1,705.62","Selling/general/admin. expenses, total":"1,198.93","Research & development":"24.79","Depreciation/amortization":"43.69","Interest exp.(inc.),net-operating, total":"98.63","Unusual expense (income)":"0.84","Other operating expenses, total":"(19.30)","Total operating expense":"2,492.54","Operating income":"358.04","Other, net":"7.69","Net income before taxes":"365.74","Provision for income taxes":"72.55","Net income after taxes":"293.19","Minority interest":"(1.80)","Net income before extra. items":"291.38","Net income":"291.38","Income available to com excl extraord":"291.38","Income available to com incl extraord":"291.38","Diluted net income":"291.38","Diluted weighted average shares":"1,411.20","Diluted eps excluding extraord items":"0.21","Dps - common stock primary issue":"0.22","Diluted normalized eps":"0.21","Gain (loss) on sale of assets":"11.17"},"Balance sheet":{"Cash":"0.16","Cash & equivalents":"1,112.24","Cash and short term investments":"1,112.41","Accounts receivable - trade, net":"1,553.65","Total receivables, net":"2,312.79","Total inventory":"1,006.95","Prepaid expenses":"124.02","Other current assets, total":"25.60","Total current assets":"4,581.77","Property/plant/equipment, total - gross":"1,237.22","Accumulated depreciation, total":"(502.75)","Property/plant/equipment, total - net":"734.47","Goodwill, net":"20.58","Intangibles, net":"319.61","Long term investments":"1,293.20","Other long term assets, total":"109.28","Total assets":"7,058.92","Accounts payable":"161.89","Accrued expenses":"56.53","Notes payable/short term debt":"2,283.83","Current port. of  lt debt/capital leases":"10.00","Other current liabilities, total":"156.45","Total current liabilities":"2,668.70","Long term debt":"212.85","Total long term debt":"212.85","Total debt":"2,506.68","Deferred income tax":"19.10","Minority interest":"84.23","Other liabilities, total":"13.49","Total liabilities":"2,998.38","Common stock, total":"1,411.20","Additional paid-in capital":"135.92","Retained earnings (accumulated deficit)":"2,513.38","Other equity, total":"0.04","Total equity":"4,060.54","Total liabilities & shareholders' equity":"7,058.92","Total common shares outstanding":"1,411.20","Tangible book value per share, common eq":"2.64"},"Cash flow":{"Cash receipts":"3,033.56","Cash payments":"(886.33)","Cash taxes paid":"(475.83)","Changes in working capital":"(1,204.00)","Cash from operating activities":"467.41","Capital expenditures":"(121.91)","Other investing cash flow items, total":"(412.60)","Cash from investing activities":"(534.50)","Financing cash flow items":"(1.00)","Total cash dividends paid":"(214.79)","Issuance (retirement) of debt, net":"840.00","Cash from financing activities":"624.21","Foreign exchange effects":"(0.01)","Net change in cash":"557.12"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"9.35","52 Week High":"11.20","52 Week Low":"7.99","Pricing date":"","10 Day Average Trading Volume":"19.05","Market Capitalization":"13,194.72","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"235.77","Beta":"1.27","1 Day Price Change":"2.63","13 Week Price Return (Daily)":"13.47","26 Week Price Return (Daily)":"3.09","5 Day Price Return (Daily)":"6.86","52 Week Price Return (Daily)":"3.66","Year To Date Price Return (Daily)":"7.35","Month to Date Price Return (Daily)":"12.65","Price Relative to S&P500 (4 Week)":"0.76","Price Relative to S&P500 (13 Week)":"-10.79","Price Relative to S&P500 (26 Week)":"-19.26","Price Relative to S&P500 (52 Week)":"-29.56","Price Relative to S&P500 (YTD)":"-17.90"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.21","EPS excl. Extra Items (TTM)":"0.16","EPS Normalized (Annual)":"0.21","Revenue per Share (Annual)":"2.02","Revenue per Share (TTM)":"2.07","Book Value (Per Share Annual)":"2.88","Book Value (Per Share Quarterly)":"2.94","Tangible Book Value (Per Share Annual)":"2.64","Tangible Book Value (Per Share Quarterly)":"2.70","Cash Per Share (Per Share Annual)":"0.79","Cash Per Share (Per Share Quarterly)":"0.45","Cash Flow (Per Share Annual)":"0.27","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.22","Dividends (Per Share TTM)":"0.22","EBITD (Per Share TTM)":"0.28","EPS Basic excl. Extra Items (Annual)":"0.21","EPS Basic excl. Extra Items (TTM)":"0.16","EPS incl. Extra Items (Annual)":"0.21","EPS incl. Extra Items (TTM)":"0.16","Free Cash Flow (Per Share TTM)":"0.12","Dividend (Per Share 5Y)":"0.11"},"Valuation":{"P/E excl. Extra Items (Annual)":"45.28","P/E excl. Extra Items (TTM)":"60.27","P/E Normalized (Annual)":"45.18","Price to sales (Annual)":"4.63","Price to sales (TTM)":"4.51","Price to Tangible Book (Annual)":"3.55","Price to Tangible Book (Quarterly)":"3.47","Price to Free Cash Flow (Per Share Annual)":"100.94","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"77.96","Price to Book (Annual)":"3.25","Price to Book (Quarterly)":"3.18","P/E Basic excl. Extra Items (TTM)":"53.76","P/E excl. Extra Items High (TTM)":"88.02","P/E excl. Extra Items Low (TTM)":"21.92","P/E incl. Extra Items (TTM)":"60.27","Net Debt (Interim)":"1,963.08","Net Debt (Annual)":"1,394.27","Dividend Yield (5Y)":"0.70","Dividend Yield":"2.35","Current Dividend Yield (TTM)":"2.35"},"Financial Strength":{"Free Cash Flow (Annual)":"130.72","Current Ratio (Annual)":"1.72","Net Interest coverage (Annual)":"4.64","Long Term Debt/Equity (Annual)":"5.24","Payout Ratio (Annual)":"106.55","Quick Ratio (Annual)":"1.34","Total Debt/Total Equity (Annual)":"61.73","Current EV/Free Cash Flow (Annual)":"347.16","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.76","Long Term Debt/Equity (Quarterly)":"6.29","Quick Ratio (Quarterly)":"1.40","Total Debt/Total Equity (Quarterly)":"62.80","Free Cash Flow (TTM)":"169.25","Net Interest Coverage (TTM)":"3.68","Payout Ratio (TTM)":"141.81"},"Margins":{"Gross Margin (Annual)":"59.83","Gross Margin (TTM)":"57.27","Net Profit Margin % (Annual)":"10.29","Net Profit Margin (TTM)":"7.50","Operating Margin (Annual)":"12.56","Operating Margin (TTM)":"9.82","Pretax Margin (TTM)":"9.88","Pretax Margin (Annual)":"12.83","Operating Margin (5Y)":"21.17","Pretax Margin (5Y)":"21.55","Free Operating Cash Flow/Revenue (5Y)":"-1.46","Free Operating Cash Flow/Revenue (TTM)":"5.79","Gross Margin (5Y)":"61.37","Net Profit Margin (5Y)":"18.12"},"Management Effectiveness":{"Return on Assets (Annual)":"4.50","Return on Equity (TTM)":"3.16","Return on Average Equity (Annual)":"7.35","Return on Average equity (TTM)":"5.36","Return on Investment (Annual)":"7.15","Return on Investment (TTM)":"5.08","Return on Average Assets (5Y)":"9.51","Return on Average Equity (5Y)":"14.08","Return on Investment (5Y)":"13.99","Asset Turnover (Annual)":"0.44","Asset Turnover (TTM)":"0.42","Inventory Turnover (Annual)":"1.22","Inventory Turnover (TTM)":"1.34","Net Income/Employee (Annual)":"50,772.61","Net Income/Employee (TTM)":"36,795.95","Receivables Turnover (Annual)":"1.81","Receivables Turnover (TTM)":"1.39","Revenue/Employee (Annual)":"493,650.60","Revenue/Employee (TTM)":"490,422.30"},"Growth":{"Revenue Growth (Quarterly YoY)":"10.34","Revenue Growth Rate (5Y)":"12.60","EPS Growth (Quarterly YoY)":"-46.20","EPS Growth (TTM YoY)":"-61.67","EPS Growth Rate (5Y)":"-1.26","Dividend Growth Rate (3Y)":"40.10","Revenue Growth (TTM YoY)":"-7.53","Revenue Growth (Per Share 5Y)":"12.60","Revenue Growth Rate (3Y)":"8.79","EPS Growth Rate (3Y)":"-15.46","Book Value Growth Rate (Per Share 5Y)":"11.83","Tangible Book Value Total Equity CAGR (5Y)":"12.23","Capital Spending growth rate 5 year":"4.79","EBITDA CAGR (5Y)":"3.30","EBITDA Interim CAGR (5Y)":"-0.82","Free Operating Cash Flow CAGR (5Y)":"-3.04","Total Debt CAGR (5Y)":"27.24","Net Profit Margin Growth Rate (5Y)":"-12.46"},"Income Statement":{"Revenue (Annual)":"2,850.59","Revenue (TTM)":"2,923.41","EBITD (Annual)":"543.28","EBITD (TTM)":"394.49","Earnings Before Taxes (Annual)":"365.74","Earnings Before Taxes (TTM)":"288.94","Net Income to Common (Annual)":"291.38","Net Income to Common (TTM)":"218.93","Earnings Before Taxes Normalized (Annual)":"366.57","Net Income Available to Common Normalized (Annual)":"292.05","Diluted Normalized EPS excl. Extra Items (TTM)":"0.16"}}}